Pharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+8.97%
About This Group of Stocks
Our Expert Thinking
This collection focuses on the world's most influential pharmaceutical companies driving medical breakthroughs. These firms are developing groundbreaking treatments for widespread chronic conditions like diabetes, obesity, and cancer, which are seeing increased global demand. The theme captures companies at the forefront of healthcare innovation that directly impact medical outcomes worldwide.
What You Need to Know
This group includes established pharmaceutical giants alongside innovative biotechnology companies and healthcare supply chain providers. These are large, well-established companies with strong market positions and proven track records. The selection offers diversified exposure to different aspects of the healthcare industry, from drug development to distribution.
Why These Stocks
These specific companies were handpicked for their leadership positions in pharmaceutical innovation and their potential to benefit from growing global healthcare demands. The selection includes industry titans like Eli Lilly, known for successful GLP-1 drugs, alongside other established leaders like Johnson & Johnson and Pfizer, providing a balanced approach to pharmaceutical investing.
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 8.97% over the next year.
Stocks Rated Buy by Analysts
4 of 6 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 4.7% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Medical Breakthrough Momentum
These pharmaceutical giants are developing revolutionary treatments for conditions affecting millions globally. From Eli Lilly's successful GLP-1 drugs to other innovative therapies, these companies are at the cutting edge of medical advancement.
Growing Global Health Demand
As populations worldwide increasingly seek advanced healthcare solutions, these industry leaders are positioned to benefit from rising demand for innovative treatments and medical technologies.
Industry Titans with Proven Track Records
This collection features established pharmaceutical powerhouses with decades of experience, strong market positions, and consistent innovation pipelines that have delivered results for investors over time.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Fed Pivot Play: Financial Sector's Risk-Reward Trade
An unexpected drop in wholesale prices has increased the likelihood that the Federal Reserve will cut interest rates to support the economy. This potential shift in monetary policy creates opportunities for companies in sectors that are sensitive to lower borrowing costs, such as banking and financial services.
Financial Giants (JPM, GS, V, MA) Investment Guide
As Africa's economic landscape matures, its ties to the world's leading financial institutions are deepening. This basket offers exposure to a selection of these global financial giants, including investment banks and payment innovators with a strategic footprint on the continent.
AI Infrastructure: Beyond Oracle's Historic Deal
Oracle's historic $300 billion deal to provide OpenAI with massive computing power highlights the surging demand for AI infrastructure. This creates a significant investment opportunity in the companies building the essential components for next-generation data centers.
Frequently Asked Questions
Everything you need to know about the product and billing.